Fresenius Kabi opens production facility in Indonesia
November 24, 2017
From left to right: Christoph Funke (Executive Vice President of Global Manufacturing Pharmaceuticals, Pharmaceuticals Division, Fresenius Kabi); Indrawati Taurus (President Director of PT ETHICA Industri Farmasi, a Joint Venture with Fresenius Kabi); Prof. Dr. Dr. Nila Djuwita F. Moeloek, Sp.M (K) (Minister of Health of The Republic of Indonesia); Ir. Airlangga Hartarto, MBA, MMT (Minister of Industry of The Republic of Indonesia); Eng Liang Tan (President Commissioner of SOHO Global Health), Gerrit Steen (Fresenius Kabi President Region Asia and Board Member of Fresenius Kabi); Sjariff Mahri (Plant Head of PT ETHICA Industri Farmasi, Jababeka, Cikarang, Indonesia)
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.